Continuation treatment of major depressive disorder: Is there a case for duloxetine?

Drug Design, Development and Therapy

Volumn , Issue 4, 2010, Pages 19-31

  Norman, Trevor R ^a   Olver, James S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clinical trials; Continuation treatment; Duloxetine; Major depression; Placebo studies; Relapse prevention

Indexed keywords

DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; VENLAFAXINE; ANTIDEPRESSANT AGENT; THIOPHENE DERIVATIVE;

ABNORMAL DREAMING; ACCIDENTAL INJURY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGINA PECTORIS; ANOREXIA; ANTIDEPRESSANT ACTIVITY; ANXIETY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOMUTILATION; BABESIOSIS; BACKACHE; CHOLELITHIASIS; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CONVULSION; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FALLING; FATIGUE; FLATULENCE; HEART PALPITATION; HEART RATE; HIP FRACTURE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOMANIA; INFLUENZA; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LUNG EDEMA; MAJOR DEPRESSION; MANIA; NAUSEA; NEPHROLITHIASIS; ORTHOSTATIC HYPOTENSION; PAIN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; QT PROLONGATION; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; RHINOPHARYNGITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYNCOPE; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; THIOPHENES;

EID: 77953665611     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/dddt.s4358     Document Type: Review

References (58)

1. World Health Organization. Factsheet: Depression 2008. Available from: http://www.who.int/mental_health/management/depression/definition/en/. Accessed September 11, 2008.
2. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156:1000-1006.
3. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
4. Paykel ES, Ramana R, Cooper Z, et al. Prevention of relapse in residual depression an important outcome in depression. Psychol Med. 1995;25:1171-1180.
5. Mann JJ. The medical management of depression. N Engl J Med. 2005;353:1819-1834.
6. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with anti-depressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:651-653.
7. Coppen A, Ghose K, Montgomery S, Rama RV, Bailey J, Jorgensen A. Continuation therapy with amitriptyline in depression. Br J Psychiatry. 1978;133:28-33.
8. Glen AI, Johnson AL, Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomised double-blind, controlled trial. Psychol Med. 1984;14:37-50.
9. Kane JM, Quitkin FM, Rifkin A, Ramos L, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry. 1982;39:1065-1069.
10. Prien RF, Klett CJ, Caffey EM. Lithium carbonate and imipramine in the prevention of affective episodes. Arch Gen Psychiatry. 1973;29: 420-425.
11. Prien RF, Kupfer DJ, Mansky PA. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine and a lithium carbonate-imipramine combination. Arch Gen Psychiatry. 1984;41:1096-1104.
12. Alexopoulos GS, Meyers BS, Young RC. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry. 2000;57:285-290.
13. Kocsis JH, Friedman RA, Markowitz JC. Maintenance therapy for chronic depression. A controlled clinical trial of desipramine. Arch Gen Psychiatry. 1996;53:769-774.
14. Robinson RS, Lerfald SC, Bennett B. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull. 1991;27:31-39.
15. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry. 1989;46:783-786.
16. Montgomery SA, Dufour H, Brion S. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry. 1988;3(Suppl): 69-76.
17. Gilaberte I, Montejo AL, de la Gandara J. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol. 2001;21:417-424.
18. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry. 1992;160:217-222.
19. Wilson KC, Mottram PG, Ashworth L, Abou-Saleh MT. Older community residents with depression: long-term treatment with sertraline, double-blind, placebo-controlled study. Br J Psychiatry. 2003;182: 492-497.
20. Eric L. A prospective, double-blind comparative multi-centre study of paroxetine in preventing recurrent major depressive episodes. Biol Psychiatry. 1991;29:11-14.
21. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psy-chopharmacol. 1993;8:189-195.
22. Reynolds CF, Dew MA, Pollock BG. Maintenance treatment of major depression in old age. N Engl J Med. 2006;354:1130-1138.
23. Hochstrasser B, Isaksen PM, Koponen H. Prophylactic effect of citalopram in unipolar recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry. 2001;178:304-310.
24. Klysner R, Bent-Hansen J, Hansen HL. Efficacy of citalopram in the pre-vention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry. 2002;181:29-35.
25. Kornstein SG, Bose A, Li DY, Saikali KG, Gandhi C. Escitalopram maintenance treatment for prevention of recurrent depression: A randomised, placebo-controlled trial. J Clin Psychiatry. 2006;67: 1767-1775.
26. RMA, Schatzberg AF. Long-term management of depression. Am J Med. 1994;97(Suppl 6A):33S-38S.
27. Rouillon F, Berdeaux G, Bisserbe JC. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. J Affect Disord. 2000;58:171-180.
28. Kocsis JH, Thase ME, Trivedi MH, et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. J Clin Psychiatry. 2007;68: 1014-1023.
29. Keller MB, Trivedi MH, Thase ME, et al. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007;68:1246-1256.
30. Kornstein SG, Kocsis JH, Ahmed S, et al. Assessing the efficacy of 2 years maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis from the PREVENT study. Int Clin Psychopharmacol. 2008;23:357-363.
31. Wong DT. Duloxetine (LY248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp Opin Invest Drugs. 1998;7:1-9.
32. Kasamo K, Blier P, de Montigny C. Blockade of serotonin and norepi-nephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther. 1996;277:278-286.
33. Bymaster FP, Dreshfield-Ahmad LJ, Threkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology. 2001;25: 871-880.
34. Turcotte JE, Debonnel G, de Montigny C, et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24:511-521.
35. Vincent S, Bieck PR, Garland EM, et al. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacologi-cal profiles. Circulation. 2004;109:3202-3207.
36. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000;40:161-167.
37. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31:1142-1150.
38. Girardi P, Pompili M, Innamorati M, et al. Duloxetine in acute major depression: review of comparisons to placebo and standard antide-pressants using dissimilar methods. Hum Psychopharmacol. 2009;24: 177-190.
39. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry. 2003;64:1237-1244.
40. Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 years and older: an open-label study. BMC Geriatrics. 2004; 4:11.
41. Dunner DL, Wilson M, Fava M, et al. Long-term tolerability and effec-tiveness of duloxetine in the treatment of major depressive disorder. Depress Anxiety. 2008;25:E1-E8.
42. Wohlreich MM, Martinez JM, Mallinckrodt CH, et al. An open-label study of duloxetine for the treatment of major depressive disorder. J Clin Psychopharmacol. 2005;25:552-560.
43. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder. Double-blind placebo-controlled study. Br J Psychiatry. 2006;188:346-353.
44. Perahia DGS, Maina G, Thase M, et al. Duloxetine in the prevention of depressive recurrences: a randomised, double-blind, placebo controlled study. J Clin Psychiatry. 2009;70:706-716.
45. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14: 457-470.
46. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus dulox-etine in patients with major depressive disorder. Curr Med Res Opin. 2007;23:1605-1614.
47. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psy-chopharmacol. 2005;20:327-341.
48. Gartlehner G, Thaler K, Hansen RA, Gaynes BN. The general and comparative efficacy and safety of duloxetine: a systematic review and meta-analysis. Drug Saf. 2009;32:1159-1173.
49. Wohlreich MM, Mallinckrodt CH, Prakash BA, et al. Duloxetine for the treatment of major depressive disorder: Safety and tolerability associated with dose escalation. Depress Anxiety. 2007;24:41-52.
50. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs. 2007;21: 581-609.
51. Fermini B, Fossa AA. The impact of drug-induced QT interval prolonga-tion on drug discovery. Nat Rev Drug Discov. 2003;2:439-447.
52. Zhang L, Chappell J, Gonzales CR, et al. QT effects of duloxetine at supratherapeutic doses: A placebo and positive controlled study. J Cardiovasc Pharmacol. 2007;49:146-153.
53. Serretti A, Chiesa A. Treatment emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol. 2009;29:259-266.
54. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind, placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry. 2005;66:686-692.
55. Clayton A, Kornstein S, Prakash A, et al. Changes in sexual functioning associated with duloxetine, escitalopram and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007;4: 917-929.
56. Salem BA, Karem EG. Duloxetine and suicide attempts: a possible relation. Clin Pract Epidemiol Ment Health. 2008;4:18-19.
57. Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviours and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol. 2006;26:587-594.
58. Dunner DL, D'Souza DN, Kajdasz DK, et al. Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression. J Affect Disord. 2005;87:115-119.